Instrumentation first-half loss blamed on pricing pressures
This article was originally published in Clinica
Declining margins in haemostasis products in Europe and pricing pressures generally led to a Lit10.9 billion ($5 million) first-half loss at Instrumentation Laboratory. This is despite sales growth from acquisitions by Italian diagnostics company running at more than 10%,
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.